FDA WARNING_LETTER - Lovega LLC dba Pink Pony Peptides - December 31, 2025

On March 31, 2026, the FDA issued a warning letter to Lovega LLC, doing business as Pink Pony Peptides, following an investigation of the company’s website in December 2025. The FDA determined that the firm is illegally selling unapproved new drugs, including injectable products marketed as "GLP-2 TZ" (Tirzepatide), "GLP-3 RT" (Retatrutide), and "Bacteriostatic Water."

Under the Federal Food, Drug, and Cosmetic Act, these products are classified as drugs because they are intended to treat medical conditions, regulate blood sugar, and support weight loss. Although Pink Pony Peptides labeled these items for "research purposes only," their website marketing explicitly suggests human use. The FDA highlighted that injectable drugs pose significant public health risks because they bypass the body’s natural defenses, potentially leading to life-threatening infections if they are not properly regulated and manufactured.

By selling these products without approved applications, the company has violated federal laws regarding the introduction of unapproved new drugs into interstate commerce. The FDA has mandated that Lovega LLC provide a written response within 15 working days detailing the corrective actions taken to address these violations. Failure to comply could result in legal consequences, including product seizure or an injunction.